Meeder Asset Management Inc Halozyme Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $22,000 - $29,566	-571 Reduced 77.06%	170 $7,000
Q2 2022 Aug 08, 2022	BUY	$37.35 - $48.3 $19,123 - $24,729	512 Added 223.58%	741 $33,000
Q1 2022 May 10, 2022	BUY	$31.97 - $41.06 $7,321 - $9,402	229 New	229 $9,000
Q4 2021 Feb 11, 2022	SELL	$31.82 - $40.75 $3,436 - $4,401	-108 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$38.47 - $46.42 $2,269 - $2,738	-59 Reduced 35.33%	108 $4,000
Q2 2021 Aug 09, 2021	BUY	$38.84 - $51.31 $2,097 - $2,770	54 Added 47.79%	167 $8,000
Q1 2021 Apr 28, 2021	BUY	$39.51 - $51.45 $3,871 - $5,042	98 Added 653.33%	113 $5,000
Q4 2020 Feb 09, 2021	SELL	$25.81 - $43.62 $5,136 - $8,680	-199 Reduced 92.99%	15 $1,000
Q2 2020 Aug 11, 2020	BUY	$16.25 - $26.81 $3,477 - $5,737	214 New	214 $6,000
Q1 2020 May 15, 2020	SELL	$13.9 - $21.83 $291 - $458	-21 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$14.93 - $19.53 $313 - $410	21 New	21 $0
Q1 2019 Apr 16, 2019	SELL	$13.94 - $17.58 $13,703 - $17,281	-983 Closed	0 $0
Q4 2018 Jan 17, 2019	SELL	$13.33 - $18.66 $34,991 - $48,982	-2,625 Reduced 72.75%	983 $14,000
Q3 2018 Nov 02, 2018	SELL	$16.68 - $18.41 $23,568 - $26,013	-1,413 Reduced 28.14%	3,608 $0
Q2 2018 Jul 24, 2018	BUY	$16.87 - $20.3 $68,627 - $82,580	4,068 Added 426.86%	5,021 $0
Q1 2018 May 03, 2018	BUY	$17.06 - $21.2 $16,258 - $20,203	953 New	953 $19,000
Q4 2017 Feb 02, 2018	SELL	$16.75 - $20.8 $3,082 - $3,827	-184 Closed	0 $0
Q3 2017 Oct 20, 2017	BUY	$11.76 - $17.4 $2,163 - $3,201	184	184 $3,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.